• news.cision.com/
  • Observe Medical ASA/
  • Observe Medical: Scientific article provides evidence of Sippi® technology reducing microbial biofilm formation - a risk factor for patient infection

Observe Medical: Scientific article provides evidence of Sippi® technology reducing microbial biofilm formation - a risk factor for patient infection

Report this content

A recently published article demonstrates that the patented Sippcoat® technology, an integrated part of Sippi® system, from Observe Medical, significantly reduces microbial biofilm formation in medical devices, suggesting a new strategy for reducing hospital-acquired infections.

The article “Making medical devices safer: impact of plastic and silicone oil on microbial biofilm formation” was recently published in Journal of Hospital Infection, Volume 106, Issue 1, P155-162, 2020 (Link to the article).

Medical devices face the challenge of formation of microbial biofilm (treatment-resistant colonies of bacteria and fungi), on their surfaces. Biofilm increases the risk of patient infection, and the risk of device malfunction. Efficient and reliable methods to reduce biofilm formation are until now lacking.

The article is based on an independent, investigator-initiated study, which evaluated a new method, using a silicone oil (patented Sippcoat® technology used in Sippi®) to limit biofilm formation.

In the article Dr. Martin Slettengren and colleagues at Karolinska Institutet, Sweden, demonstrate that silicon oil significantly decreases biofilm formation -a risk factor for both patient infection and device malfunction, from a series of bacteria, including several multi-resistant strains, and from fungi (p<0.001-0.0001). This suggests a new strategy to reduce hospital-acquired infections and make medical device function safer.

“Cather-associated urinary tract infection (CAUTI) is a significant clinical complication, causing both patient suffering and added costs for the healthcare system. This article shows that silicone oil, a patented Sippcoat® technology used in Sippi® system, significantly reduces biofilm formation, thereby lowering the risk for bacterial migration and patient infection. This is fully in line with the mission of Observe Medical, to improve the clinical outcome for patients and enable a more efficient care system, by improved urine monitoring with the Sippi® system, - a clinical need further highlighted by the current Covid-19 situation” says Björn Larsson, CEO of Observe Medical.

For further information, please contact:

Björn Larsson, CEO, Observe Medical ASA
Mobile: + 46 76 620 17 25
E-mail: bjorn.larsson@observemedical.com

About Observe Medical

Observe Medical develops and markets innovative hospital products that contribute to increased patient safety and a more efficient care system. The company's headquarter is in Oslo and its operations are based out of Sweden. Observe Medical's initial product Sippi®, is the only automated digital urine meter with wireless data transfer to hospital patient data management systems, and hinders bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is CE marked and is currently being launched at selected hospitals in Europe.